Nomura Holdings
MRSN

Nomura Holdings’s Mersana Therapeutics MRSN Stock Holding History

Nomura Holdings’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,192
Closed -$180K – 1539
2023
Q2 		$180K Buy
+2,192
New +$321K ﹤0.01% 1173
2020
Q4 		– Sell
-1,376
Closed -$642K – 1606
2020
Q3 		$642K Buy
+1,376
New +$695K ﹤0.01% 924

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Nomura Holdings's MRSN Position: Q3 2023 in Review

Nomura Holdings sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 5,959 shares — an estimated $490K sold.

Nomura Holdings first reported a position in MRSN in Q4 2021 and held it in 2 quarters. The position peaked at $609K in Q4 2021. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Nomura Holdings reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Nomura Holdings sold 5,959 Mersana Therapeutics shares in Q3 2023, an estimated $490K.
  • Nomura Holdings first reported a position in Mersana Therapeutics in Q4 2021 and held it in 2 quarters.
  • Nomura Holdings's Mersana Therapeutics position peaked at $609K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Nomura Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.